Dr. Hakkı Gürsöz, president of the Turkish Medicines and Medical Devices Agency (TiTCK), provides insights into recent localization and pricing policies and delivers strong messages to both domestic and foreign companies operating in Turkey while underlining TiTCK’s ambitions to work hand-in-hand with the industry, the world’s most respected regulatory authorities and international organizations to further move the Turkish healthcare ecosystem forward.
Founded in November 2011, TITCK is a relatively young regulatory agency. You have been one of TITCK’s key executives since the very beginning, first as vice president and then as president since July 2016. Could you give an overview of the structural dynamics and principles that have been guiding the development of TITCK over the past seven years?
“Turkey is engaged in a two-way transformation process impacting both its health system and its healthcare industry – and TiTCK stands as a key driver behind this dual dynamic”
